Teleflex Incorporated Stock News

The addition to the IABP family supports uncompromised cardiac support for patients during transport The addition to the IABP family supports uncompromised cardiac support for patients during transport

WAYNE, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that the preliminary results from its Ringer™ PBC IDE study were reported in a featured presentation at the CTO Plus Conference in New York by the study's principal investigator, David E. Kandzari, MD, FACC, MSCAI, Chief, Piedmont Heart Institute a...

WAYNE, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that new findings from the CLEAR study were presented at the 40th Annual European Association of Urology (EAU) Congress in Madrid, which took place March 21-24, 2025. Among the results, the study showed better early patient satisfaction and sexual ...

BOSTON--(BUSINESS WIRE)-- #MedTech--AcuityMD, the intelligence platform for MedTech, announced impressive growth and milestone achievements in 2024. Over the past year, AcuityMD contracted with its 300th customer, launched two innovative products, and doubled its staff. Further, after a $45 million Series B funding in June 2024, AcuityMD has now raised more than $83 million. With the global med...

Teleflex's (TFX 2.89%) fourth-quarter 2024 earnings conference call, held on February 27, 2025, revealed significant strategic shifts for the medical device company. In a transformative announcement, Teleflex outlined plans to acquire the Vascular Intervention business from Biotronik and separate into two publicly traded companies.

WAYNE, Penn.--(BUSINESS WIRE)-- #CLI--Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiativ...

Teleflex's management announced a significant acquisition and business split, but the market reacted negatively, dropping the shares over 20%. Fourth quarter earnings and 2025 guidance show weak revenue growth and margin leverage, with potential risks from tariffs and poor execution in key areas. The acquisition of BIOTRONIK's vascular intervention business is risky; it expands Teleflex's vascu...

Teleflex Incorporated (NYSE:TFX ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Lawrence Keusch - VP-IR & Strategy Development Liam Kelly - Chairman, President & CEO Thomas Powell - EVP & CFO John Deren - Corporate VP and Chief Accounting Officer Conference Call Participants Patrick Wood - Morgan Stanley Matthew O'Brien - Piper Sandler Jayson Bedford - Raymo...